The company said it would retain its transdermal drug delivery components business.

Embedding microfluidic architectures with microneedles enables fluid management capabilities that present new degrees of freedom for transdermal drug delivery.

Scientists at the University of Warwick and spin-off company Medherant say their TEPI patch could revolutionize the transdermal drug delivery market.

A transdermal drug delivery system (Scopoderm TTS) was developed to circumvent these problems as well as the variability in gastric absorption.

To demonstrate a potential application, a microfluidic-enabled microneedle architecture was printed to render hydrodynamic mixing and transdermal drug delivery within a single device.

Over the last decade, the use of microneedle array technology has been the focus of extensive research in the field of transdermal drug delivery.